Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.43 |
| ▸ | PDE1A | P54750 | 1/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | CFD | P00746 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4186970 | 0.95 | PDE1A (0.44) | PARP1PDE1APDE1BPDE4BPDE4D | |
| SCHEMBL4197165 | 0.93 | PDE1A (0.51) | PARP1PDE1APDE1BPDE4BPDE4D | |
| SCHEMBL4192248 | 0.92 | PDE1A (0.42) | PARP1PDE1APDE1BPDE4BPDE4D | |
| SCHEMBL4187720 | 0.92 | PDE1A (0.45) | PARP1PDE1APDE1BPDE4BPDE4D | |
| SCHEMBL4197168 | 0.89 | PDE1A (0.50) | PARP1PDE1APDE1BPDE4BPDE4D | |
| SCHEMBL4183631 | 0.88 | PDE1A (0.42) | PARP1PDE1APDE1BPDE4BPDE4D | |
| SCHEMBL4192370 | 0.88 | PDE1A (0.42) | PARP1PDE1APDE1BPDE4BPDE4D | |
| SCHEMBL4190234 | 0.88 | PARP1 (0.45) | PARP1PDE1APDE1BPDE4BPDE4D | |
| SCHEMBL4192513 | 0.88 | PDE1A (0.52) | PARP1PDE1APDE1BPDE4BPDE4D | |
| SCHEMBL4187892 | 0.88 | PDE1A (0.41) | PARP1PDE1APDE1BPDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1925617-B1 | HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF | ASKA PHARM CO LTD (JP) | 2012-11-14 | — | — | EP | claimed |
| EP-1925617-B1 | HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF | ASKA PHARM CO LTD (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-8193356-B2 | Heterocycle compound, and production process and application thereof | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20090131467-A1 | Heterocycle Compound, and Production Process and Application Thereof | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1925617-A1 | HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF | ASKA Pharmaceutical Co., Ltd. (JP) | 2008-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131467-A1 | Heterocycle Compound, and Production Process and Application Thereof | PDE3B, PDE4B, PDE7A | PARP1 916/4885PDE1A 26/4885PDE1B 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.